Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms

Blood (2021) 138 (Supplement 1): 3271.

https://doi.org/10.1182/blood-2021-145927

Published: 2021

Journal Articles

Real World Outcomes of Liposomal Daunorubicin and Cytarabine Versus 7+3 in Patients with Secondary Acute Myeloid Leukemia

Ellen Madarang, PharmD, Jillian Lykon, PharmD, Nina Nguyen, MD, Justin M. Watts, MD, Terrence J Bradley, MD, Namrata S Chandhok, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-142595

Published: 2020

Journal Articles

A Multi-Center Open-Labeled Phase II Study of Intensive Salvage Therapy Followed By Enasidenib Maintenance for Patients with Relapsed/Refractory IDH2 mutant AML

Swapna Thota, MD, Terrence J Bradley, MD, Hetty E. Carraway, MD MBA, Elizabeth A. Griffiths, MD

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-141393

Published: 2020

Journal Articles

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Yehuda E. Deutsch, MD, Robert Wilkinson, PharmD, Amanda Brahim, PharmD, Stephanie Boisclair, MD, Jose Sandoval-Sus, MD, Annie Kuehnel, APRN, Terrence J Bradley, MD, Chetasi Talati, MD, Ellen Madarang, PharmD, Jillian Lykon, PharmD, Justin M. Watts, MD, David A Sallman, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Hugo F. Fernandez, MD

Blood (2019) 134 (Supplement_1): 3896.

https://doi.org/10.1182/blood-2019-129331

Published: 2019

Journal Articles

Exceptional Responders to Hypomethylating Agents in Myeloid Neoplasms: The Miami Experience

Venkata Thammineni, MD, Terrence J Bradley, MD, Felipe Novoa, NP, Deukwoo Kwon, Justin M. Watts, MD

Blood (2019) 134 (Supplement_1): 5107.

https://doi.org/10.1182/blood-2019-131006

Published: 2019

Journal Articles

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

Kristen Pettit, MD, Aaron T. Gerds, MD MS, Abdulraheem Yacoub, MD, Justin M. Watts, MD, Maciej Tartaczuch, MD, Terrence J Bradley, MD, Jake Shortt, MBBS FRACP FRCPA PhD, William S. Stevenson, MBBS,PhD, Natasha Joan Curtin, MDFRACP,FRCPA, James M. Rossetti, DO, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Georges Natsoulis, PhD, Amber Jones, MA, Moshe Talpaz, MD, Jennifer Peppe, BS, David M Ross, MD PhD, Hugh Young Rienhoff, Jr., MD

Blood (2019) 134 (Supplement_1): 556.

https://doi.org/10.1182/blood-2019-123244

Published: 2019

Journal Articles

A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Justin M. Watts, MD, Terrence J Bradley, MD, Amber Thomassen, Andrew M. Brunner, MD, Mark D. Minden, MD PhD, Nikolaos Papadantonakis, MDPhDMSc, Sameem Abedin, MD, Amanda J Baines, Olena Barbash, PhD, Shelby Gorman, Brandon E Kremer, MD PhD, Gautam M. Borthakur, MD

Blood (2019) 134 (Supplement_1): 2656.

https://doi.org/10.1182/blood-2019-130337

Published: 2019

Journal Articles

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

Tamara K Moyo, MD PhD, Justin M. Watts, MD, Barry S. Skikne, MD, Jason H. Mendler, MD PhD, Virginia M. Klimek, MD, Sheau-Chiann Chen, PhD, Run Fan, PhD MS, Ingrid A Anderson, PhD, Andrew Sochacki, MD, Stephen A. Strickland, MD, Michael T Byrne, DO, Terrence J Bradley, MD, Gregory D Ayers, MS, Sanjay R Mohan, MD MSCI, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 4236.

https://doi.org/10.1182/blood-2019-130003

Published: 2019

Journal Articles

The Lysine-Specific Demethylase 1 (LSD1) Inhibitor Tranylcypromine (TCP) in Combination with ATRA Is Tolerable and Has Anti-Leukemic Activity in Adult Patients with Relapsed/Refractory AML and MDS

Justin M Watts, MD, Terrence J Bradley, MD, Amber Thomassen, MA, MSN, Yvonne Trang Dinh, BS, Dalissa Tejera, MSN, Kristen Englund, Sorab Boga, MPH, Randy Astaiza, BS, Charles J Chen, MPH, Malika Abdur-Rahman, BS, MSED, Marinescu Ion, CCRC, FMG, Aymee Perez, PhD, Masoumeh Tayari, PhD, Lluis Morey, PhD, Maria E. Figueroa, MD, Ramin Shiekhattar, PhD, Arthur Zelent, PhD, Ronan Swords, MD PhD

Blood (2018) 132 (Supplement 1): 2721.

https://doi.org/10.1182/blood-2018-99-115411

Published: 2018

Journal Articles

Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia

Todd C. Knepper, PharmD, Yehuda E. Deutsch, MD, Chirag K Bhagat, PharmD, Justin M Watts, MD, Terrence J Bradley, MD, Wassim Samra, MD, Mohammad Omar Hussaini, MD, Kendra L. Sweet, MD, Chetasi Talati, MD, Eric Padron, MD, Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, David A Sallman, MD

Blood (2018) 132 (Supplement 1): 1524.

https://doi.org/10.1182/blood-2018-99-113088

Published: 2018

Journal Articles

Mutational Frequency in Hispanic and Non-Hispanic Patients with Acute Myeloid Leukemia (AML): Updated Analysis of 227 Patients

Terrence J Bradley, MD, Jorge Monge, MD, Chetasi Talati, MD, Sandra Dannielle Algaze, MD BS, Christine Angela Vaupel, PhD, Jennifer R Chapman, MD, Francisco Vega, MD PhD, Jeff Hall, Jeffrey E. Lancet, MD, Eric Padron, MD, Ronan T. Swords, MD PhD FRCPI, FRCPath, Justin M Watts, MD

Blood (2017) 130 (Supplement 1): 2699.

https://doi.org/10.1182/blood.V130.Suppl_1.2699.2699

Published: 2017

Journal Articles

Splenectomy in a Severe Case of Acquired Factor X Deficiency Secondary to Amyloidosis: Case Discussion and Review of the Literature

Terrence J Bradley, MD, Matthew P Salzberg, MD, George Nahas, DO, Basem Azab, MD, Alan Livingstone, MD, John J. Byrnes, MD, Thomas J. Harrington, MD, James E. Hoffman, MD

Blood (2017) 130 (Supplement 1): 4885.

https://doi.org/10.1182/blood.V130.Suppl_1.4885.4885

Published: 2017

NARROW

Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms

Real World Outcomes of Liposomal Daunorubicin and Cytarabine Versus 7+3 in Patients with Secondary Acute Myeloid Leukemia

A Multi-Center Open-Labeled Phase II Study of Intensive Salvage Therapy Followed By Enasidenib Maintenance for Patients with Relapsed/Refractory IDH2 mutant AML

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Exceptional Responders to Hypomethylating Agents in Myeloid Neoplasms: The Miami Experience

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

The Lysine-Specific Demethylase 1 (LSD1) Inhibitor Tranylcypromine (TCP) in Combination with ATRA Is Tolerable and Has Anti-Leukemic Activity in Adult Patients with Relapsed/Refractory AML and MDS

Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia

Mutational Frequency in Hispanic and Non-Hispanic Patients with Acute Myeloid Leukemia (AML): Updated Analysis of 227 Patients

Splenectomy in a Severe Case of Acquired Factor X Deficiency Secondary to Amyloidosis: Case Discussion and Review of the Literature

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only